Literature DB >> 15919901

Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency.

Ke Lan1, Daniel A Kuppers, Subhash C Verma, Nikhil Sharma, Masanao Murakami, Erle S Robertson.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent contributing to development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman desease. Following primary infection, latency is typically established. However, the mechanism by which KSHV establishes latency is not understood. We have reported that the latency-associated nuclear antigen (LANA) can repress RTA (for replication and transcription activator) expression by down-regulating its promoter. In this study, we show that RTA is associated with the virion particle. We also show that RTA can activate the LANA promoter and induce LANA expression in transient reporter assays. Additionally, the transcription of RTA correlates with LANA expression in the early stages of de novo infection of KSHV, and induction of LANA transcription is responsive to induction of RTA with an inducible system. This induction in LANA transcription was dependent on recombination signal sequence binding protein Jkappa (RBP-Jkappa), as a RBP-Jkappa-deficient cell line was significantly delayed and inefficient in LANA transcription with expression of RTA. These studies suggest that RTA contributes to establishment of KSHV latency by activating LANA expression in the early stages of infection by utilizing the major effector of the Notch signaling pathway RBP-Jkappa. This describes a feedback mechanism by which LANA and RTA can regulate each other and is likely to be a key event in the establishment of KSHV latency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919901      PMCID: PMC1143691          DOI: 10.1128/JVI.79.12.7453-7465.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

2.  The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen.

Authors:  L Rainbow; G M Platt; G R Simpson; R Sarid; S J Gao; H Stoiber; C S Herrington; P S Moore; T F Schulz
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus.

Authors:  D Dittmer; M Lagunoff; R Renne; K Staskus; A Haase; D Ganem
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL.

Authors:  T Heinemeyer; E Wingender; I Reuter; H Hermjakob; A E Kel; O V Kel; E V Ignatieva; E A Ananko; O A Podkolodnaya; F A Kolpakov; N L Podkolodny; N A Kolchanov
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

5.  Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Renne; C Barry; D Dittmer; N Compitello; P O Brown; D Ganem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line.

Authors:  L Gradoville; J Gerlach; E Grogan; D Shedd; S Nikiforow; C Metroka; G Miller
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator.

Authors:  C Bais; B Santomasso; O Coso; L Arvanitakis; E G Raaka; J S Gutkind; A S Asch; E Cesarman; M C Gershengorn; E A Mesri; M C Gerhengorn
Journal:  Nature       Date:  1998-01-01       Impact factor: 49.962

8.  A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Sun; S F Lin; L Gradoville; Y Yuan; F Zhu; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus.

Authors:  D H Kedes; M Lagunoff; R Renne; D Ganem
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

10.  CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex.

Authors:  J J Hsieh; S Zhou; L Chen; D B Young; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more
  70 in total

1.  Multiple defects, including premature apoptosis, prevent Kaposi's sarcoma-associated herpesvirus replication in murine cells.

Authors:  Kathryn Austgen; Scott A Oakes; Don Ganem
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

2.  Early and sustained expression of latent and host modulating genes in coordinated transcriptional program of KSHV productive primary infection of human primary endothelial cells.

Authors:  Seung Min Yoo; Fu-Chun Zhou; Feng-Chun Ye; Hong-Yi Pan; Shou-Jiang Gao
Journal:  Virology       Date:  2005-09-08       Impact factor: 3.616

Review 3.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

4.  The transcriptional repressor K-RBP modulates RTA-mediated transactivation and lytic replication of Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhilong Yang; Charles Wood
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Overexpression of the kaposi's sarcoma-associated herpesvirus transactivator K-Rta can complement a K-bZIP deletion BACmid and yields an enhanced growth phenotype.

Authors:  Taeko Kato-Noah; Yiyang Xu; Cyprian C Rossetto; Kelly Colletti; Iva Papousková; Gregory S Pari
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats.

Authors:  Subhash C Verma; Ke Lan; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Kaposi's sarcoma-associated herpesvirus transactivator RTA promotes degradation of the repressors to regulate viral lytic replication.

Authors:  Zhilong Yang; Zhangcai Yan; Charles Wood
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

Review 8.  Virion factors that target Daxx to overcome intrinsic immunity.

Authors:  Sabrina Schreiner; Harald Wodrich
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

9.  Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA.

Authors:  Jiguo Chen; Fengchun Ye; Jianping Xie; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

10.  Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.

Authors:  Ke Lan; Masanao Murakami; Bharat Bajaj; Rajeev Kaul; Zhiheng He; Runliang Gan; Michael Feldman; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2009-11-07       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.